Tensive reports positive pivotal trial top-line results showing REGENERA™ bioresorbable device may transform breast ...
Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endpoint met and encouraging secondary performance objectives at 6 months (in 94 patients) and 12 months (in 25 …